There are 2789 resources available
933P - Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Presenter: Jean-Luc van Laethem
Session: ePoster Display
934P - The TARGET study: A global investigation of advanced dosimetry for transarterial radioembolization of hepatocellular carcinoma with yttrium-90 glass microspheres
Presenter: Marnix Lam
Session: ePoster Display
997P - STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies
Presenter: Gilberto De Castro Jr.
Session: ePoster Display
998P - Investigating the potential relationship between KRAS mutations and immunotherapeutic biomarkers in lung cancer (LC)
Presenter: Zhengbo Song
Session: ePoster Display
937P - Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
Presenter: Masafumi Ikeda
Session: ePoster Display
976P - The 30-day mortality rate after first cycle of immunotherapy
Presenter: Osman Sutcuoglu
Session: ePoster Display
977P - Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Presenter: Keun-Wook Lee
Session: ePoster Display
908P - Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Presenter: Yuan-Kai Shi
Session: ePoster Display